Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Recruiting

Phase 2

MBX 1416Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Sponsor:

MBX Biosciences

Code:

NCT07029412

Conditions

Postbariatric Hypoglycemia

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

MBX 1416 (INN imapextide)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by MBX Biosciences on 2025-10-01.